Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract - 05/02/16
Abstract |
Background |
Allergen immunotherapy is an effective treatment of allergic rhinoconjunctivitis. Clinical efficacy is associated with improvement of basophil sensitivity and an increase in allergen-specific immunoglobulin concentration.
Objective |
We sought to determine whether changes in allergen component–specific serum IgE and IgG4 levels during the updosing phase of subcutaneous immunotherapy (SCIT) are biomarkers of the immunologic changes that can lead to treatment efficacy.
Methods |
Twenty-four subjects with grass pollen–induced allergic rhinoconjunctivitis were randomized 3:1 to receive SCIT (Alutard SQ) or to an open control group. IgE and IgG4 concentrations were determined for the major allergens Phl p 1 or Phl p 5 by using ImmunoCAP and for 8 grass pollen molecules by using Immuno Solid-phase Allergy Chip (ISAC) before treatment and after updosing.
Results |
Levels of specific IgE against the dominant major allergens Phl p 1 and Phl p 5 increased from a mean of 23.0 to 48.8 kU/L (P = .01, n = 18) during the updosing phase in ImmunoCAP measurements but decreased from a median of 4.6 ISAC specific units (ISU) to 2.14 ISU (P < .0001, n = 102) when measured by using ISAC against 8 grass allergen components. The updosing phase induced a specific IgG4 level increase from a median of 0 ISU before treatment to 0.83 ISU after 12 weeks (P < .0001, n = 102) but only for allergen molecules to which pretreatment-specific IgE antibodies were detected (Spearman σ = 0.72, P < .0001, n = 102).
Conclusion |
Pretreatment allergen component–specific IgE appears to determine the induction of IgG4 in the updosing phase. Induced IgG4 seems to suppress IgE levels on ISAC, resulting in a marked decrease in ISAC-measured specific IgE levels after updosing of SCIT. Thus this decrease in ISAC IgE levels can be used to monitor the blocking effect of allergen-specific immunotherapy–induced non-IgE antibodies.
Le texte complet de cet article est disponible en PDF.Key words : Grass pollen allergy, subcutaneous immunotherapy, component-resolved diagnosis, allergen component–specific IgE, allergen component–specific IgG4, molecular allergy, allergen immunotherapy biomarker
Abbreviations used : AIT, CRD, FAB, FAP, IQR, ISAC, ISU, SCIT
Plan
| The Lundbeck Foundation funded the study but had no influence on the study design. |
|
| Disclosure of potential conflict of interest: P. A. Würtzen is employed by and has stock/stock options in ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 2
P. 562-570 - février 2016 Retour au numéro
Article précédent
- Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy
- Claire Gueguen, Julien Bouley, Hélène Moussu, Sonia Luce, Magalie Duchateau, Julia Chamot-Rooke, Marc Pallardy, Vincent Lombardi, Emmanuel Nony, Véronique Baron-Bodo, Laurent Mascarell, Philippe Moingeon
- Group 2 innate lymphoid cells mediate ozone-induced airway inflammation and hyperresponsiveness in mice
- Qi Yang, Moyar Q. Ge, Blerina Kokalari, Imre G. Redai, Xinxin Wang, David M. Kemeny, Avinash Bhandoola, Angela Haczku
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?